Treatment Action Group and AVAC Statement on Pfizer/BioNTech COVID-19 Vaccine Efficacy Announcement
Statement / Press • 2020Treatment Action Group (TAG) and AVAC welcome today’s announcement that preliminary data from the efficacy trial of Pfizer/BioNTech’s mRNA COVID-19 vaccine indicates a high level of protection against COVID-19. Our organizations urge caution, however, given the very limited information that is available only through a company press release.
Treatment Action Group Statement on the High Price of Cepheid’s Xpert Test for COVID-19
Statement / Press • 2020Cepheid is profiteering during a pandemic, with dangerous consequences for countries with vulnerable populations and health systems. New York, March 27, 2020 — Treatment Action Group calls for Cepheid to immediately lower to US$ 5 the developing country price of its rapid, cartridge-based test for detecting SARS-CoV-2, the virus that causes COVID-19. The U.S. Food…
Open Letter: Time to Lower the Price of Xpert Cartridges to $5
Letters PDF • 2020TAG joined 156 organizations and individuals to demand that Cepheid lower the price of Xpert tests for TB, HIV, HCV and other diseases to improve access to rapid, accurate diagnostic testing.
US FDA COVID Vaccine Authorization Important Step Toward Ending the COVID-19 Pandemic
Statement / Press • 2020Today’s decision by the US Food and Drug Administration (FDA) to grant an Emergency Use Authorization (EUA) for the Pfizer-BioNTech mRNA vaccine is an important step toward bringing the COVID-19 pandemic under control in the United States.
Fair Pricing for Cepheid Xpert Tests (COVID-19, HIV, TB, HCV)
Webinars • 2020On Friday, April 3, Treatment Action Group (TAG) and Médecins Sans Frontières (MSF), and the Global Coalition of TB Activists (GCTA) held a webinar on the price of Xpert tests for COVID-19, TB, HIV, HCV and other diseases.
TAG Welcomes the Election of Joseph R. Biden Jr. and Kamala D. Harris
Statement / Press • 2020Treatment Action Group (TAG) congratulates President-elect Joe Biden and Vice President-elect Kamala Harris on their ascension to the highest offices of the United States. Their victory in both the popular and electoral vote is historic.
Public Investment in Bedaquiline Up to Five-Fold That of Johnson & Johnson
Statement / Press • 2020Treatment Action Group’s independent, peer-reviewed analysis found public investment in the development of bedaquiline was up to five times that of Johnson and Johnson. This finding appears in the new PLOS ONE article, “Public Investments in the Clinical Development of Bedaquiline.”
Treatment Action Group Statement on Bedaquiline Unaffordability
Statement / Press • 2020Treatment Action Group welcomes the Global Drug Facility / Stop TB Partnership's negotiation of what amounts to a 32% savings on bedaquiline, the backbone of improved, all-oral regimens for treating drug-resistant TB.
Long-Acting Injectable Cabotegravir for HIV Pre-Exposure Prophylaxis (PrEP): Promising Results from HPTN 083
Statement / Press • 2020Treatment Action Group (TAG) welcomes the news that long-acting injectable cabotegravir (CAB LA, from ViiV Healthcare) demonstrated a high level of efficacy for preventing HIV infection in cisgender men and transgender women who have sex with men in the HIV Prevention Trials Network (HPTN) 083 trial.
Efficacy News from Second COVID-19 Vaccine Trial Underscores Need for Transparency and Cooperation Between Outgoing and Incoming US Administrations
Statement / Press • 2020AVAC and Treatment Action Group (TAG) welcome today’s announcement that preliminary data from the efficacy trial of Moderna’s mRNA COVID-19 vaccine indicate high-level of protection against COVID-19.